Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Inovio’s Surge on a Coronavirus Vaccine Was Just Speculation

By Chris Lau, InvestorPlace Contributor

Investors sold off INO stock when they remembered that launching a coronavirus vaccine would take at least a few months.

Bears Are Now in Control of Amarin Stock, But Not for Long

By Chris Lau, InvestorPlace Contributor

Bears are in control of Amarin stock, and selling pressure has driven the price down. But Vascepa will drive huge success for Amarin in 2020.

TripAdvisor’s Website and App Updates Will Spur Revenue Growth

By Chris Lau, InvestorPlace Contributor

TripAdvisor needs to counter the growing competition from Google and successfully improve its website and app to boost TRIP stock.

Investors Should Buy Beyond Meat Stock Only If Shares Dip

By Chris Lau, InvestorPlace Contributor

After announcing new partnerships and expanding reach, Beyond Meat stock might have better earnings soon. But for now, only buy BYND on dips.

Google Stock Is Unmatched Despite Alphabet’s Growing Competition

By Chris Lau, InvestorPlace Contributor

Alphabet is squeezing out too many ads and faces growing competition, but Google stock's growth is still unmatched in its industry and beyond.

Aimmune’s Prospects Shine After the FDA Approves Its Allergy Drug

By Chris Lau, InvestorPlace Contributor

Aimmune Therapeutics received FDA approval for its peanut allergy drug Palforzia, and AIMT stock could soar in 2020.

What to Expect From General Electric as Its Turnaround Accelerates

By Chris Lau, InvestorPlace Contributor

General Electric is clearly in the midst of a big turnaround, and GE stock is looking like a great stock to buy now.

Here’s What Aphria Needs to Reward Investors With 41% Upside

By Chris Lau, InvestorPlace Contributor

If you are willing to hold Aphria stock for at least three years before selling, buy some shares now to make a bet on its upside potential.

7 Festive Stocks to Buy for Chinese New Year Celebrations

By Chris Lau, InvestorPlace Contributor

Despite coronavirus fears weighing on Chinese stocks, these seven companies are great stocks to buy for the year of the rat.

Apple Has Plenty of Upside Left Thanks to Its Upcoming 5G Models

By Chris Lau, InvestorPlace Contributor

Apple reported stellar first quarter earnings, including an all-time record revenue number. Apple stock looks like a long-term buy now.

Load More